Healthcare / Drug Manufacturers - Specialty & GenericNSE
$555.85
-4.00 (-0.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $153.5M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16.1B
P/E
27.7x
↑EV/EBITDA
18.9x
↑ROE
15.6%
↑Gross Margin
51.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.9%
FCF CAGR
—
FCF margin
-3.8%
FCF / Net income
-0.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.03B · net income $579.2M · FCF $-190.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.03B | $5.03B | $4.52B | $4.20B | $3.78B |
| Net Income | $579.2M | $579.2M | $508.3M | $449.7M | $398.3M |
| EBITDA | $844.0M | $844.0M | $758.8M | $681.6M | $589.3M |
| EPS | — | — | 17.58 | 15.50 | 13.63 |
| Gross Margin | 51.4% | 51.4% | 50.6% | 49.6% | 51.9% |
| Operating Margin | 12.3% | 12.3% | 11.4% | 11.4% | 11.1% |
| Net Margin | 11.5% | 11.5% | 11.3% | 10.7% | 10.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Current Ratio | 2.31 | 2.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-190.4M | $-190.4M | $153.5M | $211.9M | $112.5M |
| Returns | |||||
| ROE | 15.6% | 15.6% | 15.6% | 15.6% | 13.7% |
| Valuation | |||||
| P/E | 27.74 | 27.74 | 36.55 | 42.06 | 44.32 |
| EV/EBITDA | 18.92 | 18.92 | 23.45 | 27.40 | 28.83 |
| P/B | 4.34 | 4.34 | 5.69 | 6.56 | 6.07 |
| Growth & Yield | |||||
| Revenue Growth | 11.2% | 11.2% | 7.5% | 11.1% | — |
| EPS Growth | — | — | 13.4% | 13.7% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.8%
Start / end P/E
n/dx → n/dx
EPS bridge
17.58 → n/d
Residual
-22.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.